Promising results show that treatment with VEGF-C reduces inflammation, tissue edema, improves cardiac and lymphatic functions, and ameliorates hypertension, e.g., after ischemia and reperfusion injury [68], myocardial infarction [69,70], and angiotensin II infusion-induced chronic cardiac dysfunction [71]. The gene discussed is VEGFC; the disease is myocardial infarction.